Period of time： 2014年5期
Publisher： Informa Healthcare
Founded in： 2002
Total resources： 54
ISSN： 1474-0338
Subject： R9 Pharmacy
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Expert Opinion on Drug Safety,volume 3,issue 5
Menu
Considerations with the use of biological therapy in the treatment of rheumatoid arthritis
By Fleischmann Roy M,Iqbal Imran,Stern Richard L in (2004)
Expert Opinion on Drug Safety,volume 3,issue 5 , Vol. 3, Iss. 5, 2004-09 , pp.
Access to resources
Recommend
By Harwood PJ,Giannoudis PV in (2004)
Expert Opinion on Drug Safety,volume 3,issue 5 , Vol. 3, Iss. 5, 2004-09 , pp.Levetiracetam safety profiles and tolerability in epilepsy patients
By Briggs Deborah E,French Jacqueline A in (2004)
Expert Opinion on Drug Safety,volume 3,issue 5 , Vol. 3, Iss. 5, 2004-09 , pp.The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease
By Thompson Sarah,Lanctôt Krista L,Herrmann Nathan in (2004)
Expert Opinion on Drug Safety,volume 3,issue 5 , Vol. 3, Iss. 5, 2004-09 , pp.By Gitman Michael D,Singhal Pravin C in (2004)
Expert Opinion on Drug Safety,volume 3,issue 5 , Vol. 3, Iss. 5, 2004-09 , pp.Information technology for detecting medication errors and adverse drug events
Expert Opinion on Drug Safety,volume 3,issue 5 , Vol. 3, Iss. 5, 2004-09 , pp.Sexual dysfunction associated with antidepressant drugs
Expert Opinion on Drug Safety,volume 3,issue 5 , Vol. 3, Iss. 5, 2004-09 , pp.By Tan Eunice KH,Grattan Clive EH in (2004)
Expert Opinion on Drug Safety,volume 3,issue 5 , Vol. 3, Iss. 5, 2004-09 , pp.Safety of benzodiazepines in the geriatric population
By Madhusoodanan Subramoniam,Bogunovic Olivera J in (2004)
Expert Opinion on Drug Safety,volume 3,issue 5 , Vol. 3, Iss. 5, 2004-09 , pp.Safety and side effect profile of fluoxetine
By Wernicke Joachim F in (2004)
Expert Opinion on Drug Safety,volume 3,issue 5 , Vol. 3, Iss. 5, 2004-09 , pp.
Previous
Next